Plasma-derived product · Antagonist of SARS-CoV-2 spike protein · developed by SAb Biotherapeutics
SAB-185 is a purified human immunoglobulin G preparation of polyclonal antibodies derived from the plasma of immunized transchromosomic bovines. It binds the SARS-CoV-2 spike protein, blocking viral attachment and entry into human cells, and is studied in COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04518410 | Phase 2/3 | Coronavirus | Completed | SABS |
| NCT04468958 | Phase 1 | COVID-19 | Completed | SABS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
CoronavirusCOVID-19Covid19SARS-CoV2
Updated Nov 1, 2026. Something wrong or missing? Report it on the SABS page.
See SABS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SABS catalysts and pipeline →